LRMR (Larimar Therapeutics) Marketable Securities: $22.47 Mil (As of Mar. 2026)


LRMR Larimar Therapeutics Inc LRMR
34 GF Score
Price $4.29
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Marketable Securities?

Larimar Therapeutics LRMR +3.63% 34 Marketable Securities is $22.47 Mil as of Mar. 2026. GuruFocus rates LRMR with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Larimar Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $22.47 Mil.

Larimar Therapeutics's annual Marketable Securities increased from Dec. 2023 ($60.04 Mil) to Dec. 2024 ($150.24 Mil) but then declined from Dec. 2024 ($150.24 Mil) to Dec. 2025 ($51.44 Mil).

Larimar Therapeutics  (NAS:LRMR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Larimar Therapeutics Marketable Securities Related Terms

Larimar Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Larimar Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Larimar Therapeutics Marketable Securities Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 91.60 60.04 150.24 51.44

Larimar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.40 117.94 85.30 51.44 22.47
LRMR
34GF Score
Larimar Therapeutics Inc LRMR
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Larimar Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $22.47 Mil mean?
Larimar Therapeutics (LRMR) has a Marketable Securities of $22.47 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Larimar Therapeutics and its competitors.
Is Larimar Therapeutics' Marketable Securities too high?
Larimar Therapeutics' current Marketable Securities is $22.47 Mil. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Marketable Securities compare to XFOR and CMPX?
Larimar Therapeutics' Marketable Securities of $22.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Larimar Therapeutics and its competitors. Larimar Therapeutics's current Marketable Securities is $22.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (LRMR) has a current Marketable Securities of $22.47 Mil. The current Marketable Securities is $22.47 Mil. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Larimar Therapeutics (LRMR), the current Marketable Securities is $22.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges ZA71:Germany
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score

Get the complete analysis for LRMR

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.29
Price